{"id":52939,"date":"2026-01-06T00:04:30","date_gmt":"2026-01-05T16:04:30","guid":{"rendered":"https:\/\/flcube.com\/?p=52939"},"modified":"2026-01-06T00:04:31","modified_gmt":"2026-01-05T16:04:31","slug":"bio-sincerity-partners-with-xellar-on-ai-organoid-chip-drug-discovery-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52939","title":{"rendered":"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform"},"content":{"rendered":"\n<p><strong>Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.<\/strong> (<a href=\"SHE: 301096\">SHE: 301096<\/a>) and <strong>Xellar Biosystems<\/strong> announced a <strong>strategic cooperation agreement<\/strong> to integrate <strong>AI + organoid chip technology<\/strong> across the entire new drug R&amp;D chain. The partnership aims to tackle efficiency and success rate challenges in innovative drug development through three core directions: co\u2011building an AI\u2011organoid R&amp;D platform, establishing a drug incubation joint venture, and expanding therapies in oncology, autoimmune, neurology, and ophthalmology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-overview\">Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ), Xellar Biosystems<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>AI + 3D\u2011Wet\u2011AI organoid chip platform<\/td><\/tr><tr><td><strong>Focus Areas<\/strong><\/td><td>Oncology, autoimmune diseases, neurology, ophthalmology<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Strategic cooperation + joint venture for asset co\u2011creation<\/td><\/tr><tr><td><strong>Core Objectives<\/strong><\/td><td>Boost R&amp;D efficiency, improve success rates, accelerate differentiated therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-directions\">Strategic Directions<\/h2>\n\n\n\n<p><strong>\u2460 AI + Organoid Chip R&amp;D Platform<\/strong>: Integrate Bio\u2011Sincerity\u2019s drug R&amp;D data with Xellar\u2019s leading 3D\u2011Wet\u2011AI platform to create <strong>standardized, intelligent drug screening and validation solutions<\/strong> for industrial\u2011scale applications.<\/p>\n\n\n\n<p><strong>\u2461 Innovative Drug Incubation Joint Venture<\/strong>: Establish a jointly\u2011owned entity to <strong>efficiently incubate early\u2011stage projects<\/strong> with market potential, achieving strategic upgrade from technology empowerment to <strong>asset co\u2011creation<\/strong>.<\/p>\n\n\n\n<p><strong>\u2462 Key Disease Area Expansion<\/strong>: Prioritize oncology, autoimmune diseases, neurology, and ophthalmology by combining Xellar\u2019s precise disease models with Bio\u2011Sincerity\u2019s pipeline to <strong>accelerate development of differentiated therapies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-ai-organoid-drug-discovery\">Market Context: AI + Organoid Drug Discovery<\/h2>\n\n\n\n<p><strong>Global AI Drug Discovery Market<\/strong>: <strong>$2.5\u202fbillion<\/strong> (2025), projected to reach <strong>$8\u202fbillion<\/strong> by 2030, growing at <strong>26% CAGR<\/strong>. Organoid technology reduces <strong>preclinical attrition by 30\u201140%<\/strong>, addressing a <strong>$30\u202fbillion<\/strong> annual R&amp;D waste globally.<\/p>\n\n\n\n<p><strong>China Market Opportunity<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology<\/strong>: <strong>\u00a5120\u202fbillion<\/strong> drug market, <strong>15% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Autoimmune<\/strong>: <strong>\u00a545\u202fbillion<\/strong> market, <strong>12% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Neurology<\/strong>: <strong>\u00a535\u202fbillion<\/strong> market, <strong>10% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Ophthalmology<\/strong>: <strong>\u00a525\u202fbillion<\/strong> market, <strong>14% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Combined Addressable Market<\/strong>: <strong>\u00a5225\u202fbillion<\/strong> (US$31\u202fB) across four therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-differentiation\">Technology Differentiation<\/h2>\n\n\n\n<p><strong>Xellar\u2019s 3D\u2011Wet\u2011AI Platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High\u2011fidelity disease models<\/strong>: Patient\u2011derived organoids replicate human physiology better than 2D cell lines<\/li>\n\n\n\n<li><strong>AI integration<\/strong>: Machine learning predicts drug responses, optimizing lead selection<\/li>\n\n\n\n<li><strong>Throughput<\/strong>: Screens <strong>10,000+ compounds<\/strong> per month vs. <strong>1,000\u20112,000<\/strong> for traditional platforms<\/li>\n<\/ul>\n\n\n\n<p><strong>Bio\u2011Sincerity\u2019s Data Advantage<\/strong>: Proprietary <strong>preclinical and clinical datasets<\/strong> from <strong>oncology and CNS pipelines<\/strong> provide training data for AI models.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Technology<\/th><th>Focus<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Bio\u2011Sincerity + Xellar<\/strong><\/td><td>AI + organoid chip<\/td><td>Oncology, autoimmune, neurology, ophthalmology<\/td><td>Strategic partnership<\/td><\/tr><tr><td><strong>Insilico Medicine<\/strong><\/td><td>AI drug design<\/td><td>Broad therapeutic areas<\/td><td>Clinical\u2011stage candidates<\/td><\/tr><tr><td><strong>Atomwise<\/strong><\/td><td>AI virtual screening<\/td><td>Oncology, immunology<\/td><td>Discovery stage<\/td><\/tr><tr><td><strong>Emulate<\/strong><\/td><td>Organ\u2011on\u2011chip<\/td><td>Toxicology, disease modeling<\/td><td>Commercial platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: <strong>First integrated AI\u2011organoid incubation model<\/strong> in China, bridging technology platform to asset creation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>Investment Plan<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Joint Venture Capital<\/strong>: Estimated <strong>USD\u202f30\u201150\u202fmillion<\/strong> initial commitment from both parties<\/li>\n\n\n\n<li><strong>Platform Build\u2011out<\/strong>: <strong>USD\u202f15\u202fmillion<\/strong> for AI infrastructure and organoid standardization<\/li>\n\n\n\n<li><strong>Project Funding<\/strong>: <strong>USD\u202f5\u201110\u202fmillion<\/strong> per incubated asset<\/li>\n<\/ul>\n\n\n\n<p><strong>Revenue Model<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Licensing<\/strong>: Revenue from third\u2011party platform access<\/li>\n\n\n\n<li><strong>Asset Co\u2011ownership<\/strong>: <strong>50\/50 profit split<\/strong> on joint venture projects<\/li>\n\n\n\n<li><strong>Equity Upside<\/strong>: Potential IPO of joint venture in <strong>2028\u20112029<\/strong> at <strong>$500\u2011800\u202fmillion<\/strong> valuation<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the partnership\u2019s technology integration, joint venture formation, and pipeline acceleration. Actual results may differ materially due to R&amp;D challenges, regulatory hurdles, and market adoption of AI\u2011driven drug discovery.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52944,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,3775,3975,4526],"class_list":["post-52939","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-bio-sincerity-pharmaceutical-technology","tag-she-301096","tag-xellar-biosystems"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement to integrate AI + organoid chip technology across the entire new drug R&amp;D chain. The partnership aims to tackle efficiency and success rate challenges in innovative drug development through three core directions: co\u2011building an AI\u2011organoid R&amp;D platform, establishing a drug incubation joint venture, and expanding therapies in oncology, autoimmune, neurology, and ophthalmology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52939\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform\" \/>\n<meta property=\"og:description\" content=\"Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement to integrate AI + organoid chip technology across the entire new drug R&amp;D chain. The partnership aims to tackle efficiency and success rate challenges in innovative drug development through three core directions: co\u2011building an AI\u2011organoid R&amp;D platform, establishing a drug incubation joint venture, and expanding therapies in oncology, autoimmune, neurology, and ophthalmology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52939\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T16:04:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T16:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0510.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform\",\"datePublished\":\"2026-01-05T16:04:30+00:00\",\"dateModified\":\"2026-01-05T16:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939\"},\"wordCount\":527,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0510.webp\",\"keywords\":[\"AI\",\"Bio-Sincerity Pharmaceutical Technology\",\"SHE: 301096\",\"Xellar Biosystems\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52939#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52939\",\"name\":\"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0510.webp\",\"datePublished\":\"2026-01-05T16:04:30+00:00\",\"dateModified\":\"2026-01-05T16:04:31+00:00\",\"description\":\"Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement to integrate AI + organoid chip technology across the entire new drug R&D chain. The partnership aims to tackle efficiency and success rate challenges in innovative drug development through three core directions: co\u2011building an AI\u2011organoid R&D platform, establishing a drug incubation joint venture, and expanding therapies in oncology, autoimmune, neurology, and ophthalmology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52939\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0510.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0510.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52939#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement to integrate AI + organoid chip technology across the entire new drug R&D chain. The partnership aims to tackle efficiency and success rate challenges in innovative drug development through three core directions: co\u2011building an AI\u2011organoid R&D platform, establishing a drug incubation joint venture, and expanding therapies in oncology, autoimmune, neurology, and ophthalmology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52939","og_locale":"en_US","og_type":"article","og_title":"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform","og_description":"Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement to integrate AI + organoid chip technology across the entire new drug R&D chain. The partnership aims to tackle efficiency and success rate challenges in innovative drug development through three core directions: co\u2011building an AI\u2011organoid R&D platform, establishing a drug incubation joint venture, and expanding therapies in oncology, autoimmune, neurology, and ophthalmology.","og_url":"https:\/\/flcube.com\/?p=52939","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-05T16:04:30+00:00","article_modified_time":"2026-01-05T16:04:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0510.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52939#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52939"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform","datePublished":"2026-01-05T16:04:30+00:00","dateModified":"2026-01-05T16:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52939"},"wordCount":527,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52939#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0510.webp","keywords":["AI","Bio-Sincerity Pharmaceutical Technology","SHE: 301096","Xellar Biosystems"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52939#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52939","url":"https:\/\/flcube.com\/?p=52939","name":"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52939#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52939#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0510.webp","datePublished":"2026-01-05T16:04:30+00:00","dateModified":"2026-01-05T16:04:31+00:00","description":"Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement to integrate AI + organoid chip technology across the entire new drug R&D chain. The partnership aims to tackle efficiency and success rate challenges in innovative drug development through three core directions: co\u2011building an AI\u2011organoid R&D platform, establishing a drug incubation joint venture, and expanding therapies in oncology, autoimmune, neurology, and ophthalmology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52939#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52939"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52939#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0510.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0510.webp","width":1080,"height":608,"caption":"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52939#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0510.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52939"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52939\/revisions"}],"predecessor-version":[{"id":52947,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52939\/revisions\/52947"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52944"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}